探索用于间歇性囊炎/膀疼痛综合征的药物重用:定义新的治疗点
Güldal Inal-Gültekin1, Zeliha Çetin2, Naşide Mangır3
1Department of Physiology, Faculty of Medicine, Istanbul Okan University, Istanbul, Türkiye.
Neurourology and urodynamics
|December 26, 2024
概括
生物信息学确定了21种潜在的药物重定向候选人,以逆转间歇性囊炎/膀疼痛综合征 (IC/BPS) 的特征. 需要进一步的研究来验证这些化合物用于治疗这种慢性疼痛疾病.
科学领域:
- 生物信息学和计算生物学
- 基因组学和分子生物学
- 药理学和药物发现
背景情况:
- 间歇性囊炎/膀疼痛综合征 (IC/BPS) 是一种严重的,鲜为人知的慢性疼痛疾病,缺乏有效的治疗方法.
- 药物再利用提供了一种可行的策略,通过确定现有药物的新用途来加速IC/BPS新疗法的开发.
- 这项研究利用生物信息学来发现能够逆转IC/BPS分子疾病特征的化合物.
研究的目的:
- 通过生物信息学分析,确定治疗间歇性囊炎/膀疼痛综合征 (IC/BPS) 的潜在候选药物.
- 发现可以逆转与IC/BPS相关的特定基因表达模式的化合物.
- 加快开发IC/BPS的新型治疗策略.
主要方法:
- 对IC/BPS患者数据集 (GSE11783,GSE28242,GSE57560) 进行了差异基因表达分析,比较了不同的表型和对照.
- 生物信息平台L1000CDS2和cMAP被用于评估IC/BPS疾病特征的逆转.
- 使用计算方法选和识别可重复使用的候选药物.
主要成果:
- 确定了21种化合物作为药物重新用途的潜在候选物.
- 已识别的化合物包括小分子,化学化合物,天然产品和FDA批准的药物.
- 这些重新设计的药物目前用于治疗癌症,骨髓纤维化和糖尿病等疾病.
结论:
- 生物信息学提供了一个强大的工具,通过分析大规模的分子数据来识别IC/BPS的治疗剂.
- 未来的体内研究对于验证已识别的重用药物的疗效至关重要.
- 扩大IC/BPS的基因组和临床数据资源将提高药物重定向努力的成功率.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
208
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
208
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
Analgesia and Pain Management
496
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
496


